Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer

Clinical Trials

Volumn 6, Issue 3, 2009, Pages 272-287

  Giobbie Hurder, Anita ^a   Price, Karen N ^a,b   Gelber, Richard D ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; LETROZOLE; PROGESTERONE RECEPTOR; STEROID RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RESEARCH; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; METHODOLOGY; MONOTHERAPY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; NITRILES; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RESEARCH DESIGN; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 67649378994     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774509105380     Document Type: Article

References (14)

1. World Health Organization, GLOBOCAN 2002: Cancer incidence, mortality, and prevalence worldwide Available at: http://www.dep.iarc.fr. Accessed 6 March 2008.
2. Early Breast Cancer Trialists' Cooperative Group. Effects of chemotherapy and hormone therapy on recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005; 365: 1687-1717.
3. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348: 2431-42.
4. Mouridsen H., Gershanovich M., Sun Y., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for post menopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606 [Erratum, J Clin Oncol 2001; 19: 3302.].
5. Mouridsen H., Gershanovich M., Sun Y., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in post-menopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21: 2101-09.
6. Ingle IN, Dowsett M., Cuzick J., et al. Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor-positive breast cancer: Meta-analyses of randomized trials of monotherapy and switching strategies (abstract). Cancer Res 2009; 69(Suppl. 2): 12.
7. Northrop Grumman Corporation: MedDRA. Available at: http://meddramsso.com.
8. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in post-menopausal women with early breast cancer. N Engl J Med 2005; 353: 2747-57.
9. Coates AS, Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for post-menopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 2005; 25: 486-92.
10. Anderson JR, Cain KC, Gelber RD Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710-19.
11. Coombes RC, Hall E., Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in post-menopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1892. Erratum in: N Engl J Med 2004; 351: 2461. N Engl J Med 2006; 355: 1746. van de Velde, Cornelius [added].
12. Viale G., Regan MM, Maiorano E., et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for post-menopausal early breast cancer: BIG 1-98. J Clin Oncol 2007; 25: 3846-52.
13. Viale G., Giobbie- Hurder A., Regan MM, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in post-menopausal women with endocrine-responsive breast cancer: Results from trial BIG 1-98 comparing adjuvant endocrine therapy with tamoxifen versus letrozole. J Clin Oncol 2008; 26(34): 5569-75.
14. Rasmussen BB, Regan MM, Lykkesfeldt AE, et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for post-menopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008; 9: 23-28.